MA49508B1 - Procédés de traitement d'une insuffisance cardiaque avec des activateurs de sarcomères cardiaques - Google Patents
Procédés de traitement d'une insuffisance cardiaque avec des activateurs de sarcomères cardiaquesInfo
- Publication number
- MA49508B1 MA49508B1 MA49508A MA49508A MA49508B1 MA 49508 B1 MA49508 B1 MA 49508B1 MA 49508 A MA49508 A MA 49508A MA 49508 A MA49508 A MA 49508A MA 49508 B1 MA49508 B1 MA 49508B1
- Authority
- MA
- Morocco
- Prior art keywords
- heart failure
- activators
- methods
- treating heart
- subject
- Prior art date
Links
- 206010019280 Heart failures Diseases 0.000 title abstract 2
- 239000012190 activator Substances 0.000 title abstract 2
- 230000000747 cardiac effect Effects 0.000 title abstract 2
- 210000002235 sarcomere Anatomy 0.000 title abstract 2
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Cardiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Heart & Thoracic Surgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762527983P | 2017-06-30 | 2017-06-30 | |
| PCT/US2018/040181 WO2019006235A1 (en) | 2017-06-30 | 2018-06-29 | METHODS OF TREATING CARDIAC INSUFFICIENCY WITH CARDIAC SARCOMER ACTIVATORS |
| EP18745732.0A EP3645002B1 (en) | 2017-06-30 | 2018-06-29 | Methods of treating heart failure with cardiac sarcomere activators |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MA49508A MA49508A (fr) | 2020-05-06 |
| MA49508B1 true MA49508B1 (fr) | 2024-12-31 |
Family
ID=63013097
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA49508A MA49508B1 (fr) | 2017-06-30 | 2018-06-29 | Procédés de traitement d'une insuffisance cardiaque avec des activateurs de sarcomères cardiaques |
Country Status (22)
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3821882A1 (en) | 2013-03-14 | 2021-05-19 | Amgen Inc. | Heterocyclic compounds and their uses |
| JP2020526483A (ja) | 2017-06-30 | 2020-08-31 | アムジエン・インコーポレーテツド | 心筋節活性化剤で心不全を治療する方法 |
| MX2021009594A (es) | 2017-06-30 | 2022-10-24 | Amgen Inc | Sintesis de omecamtiv mecarbil. |
| DK3594199T3 (da) | 2018-07-09 | 2020-09-14 | Fis Fabbrica Italiana Sintetici Spa | Krystallinsk 2-flour-3-nitrotoluen og proces til forberedelse deraf |
| EP3837009A1 (en) | 2018-08-17 | 2021-06-23 | Amgen, Inc | Salts and crystal forms of omecamtiv mecarbil |
| SG11202112723PA (en) * | 2019-05-19 | 2021-12-30 | Myokardia Inc | Treatment of systolic dysfunction and heart failure with reduced ejection fraction with the compound(r)-4-(1-((3-(difluoromethyl)-1-methyl-1h-pyrazol-4-yl)sulfonyl)-1-fluoroethyl)-n-(isoxazol-3-yl)piperidine-1-carboxamide |
| MX2022000498A (es) | 2019-07-17 | 2022-02-03 | Cytokinetics Inc | Polimorfos de (r)-n-(5-(5-isopropil-1,2,4-oxadiazol-3-il)-2,3-dihi dro-1h-inden-1-il) -2-metil-2h- tetrazol-5-carboxamida. |
| WO2021163172A1 (en) * | 2020-02-10 | 2021-08-19 | Amgen Inc. | Omecamtiv mecarbil tablet |
| JP7832128B2 (ja) * | 2020-06-15 | 2026-03-17 | マイオカーディア，インク | 心房機能不全の治療 |
| CN116710139A (zh) * | 2020-11-12 | 2023-09-05 | 安进股份有限公司 | 通过施用奥美卡替莫卡必尔治疗心力衰竭的方法 |
| IL302850A (en) * | 2020-11-12 | 2023-07-01 | Amgen Inc | Methods of treating heart failure by administering OMECAMTIV MECARBIL |
| AU2022232919A1 (en) | 2021-03-10 | 2023-10-19 | Amgen Inc. | Synthesis of omecamtiv mecarbil |
| WO2023164452A2 (en) * | 2022-02-22 | 2023-08-31 | Yale University | Methods of treating, ameliorating, or preventing heart failure, and methods of promoting heart muscle growth |
| CA3268270A1 (en) | 2022-09-26 | 2024-04-04 | Edgewise Therapeutics, Inc. | 1,4-DIHYDROQUINAZOLINONE COMPOUNDS AND ASSOCIATED USES |
| WO2024081611A1 (en) * | 2022-10-11 | 2024-04-18 | Cytokinetics, Incorporated | Methods for treating heart failure by administering cardiac sarcomere activators |
| JP7858148B1 (ja) | 2023-03-27 | 2026-05-13 | エッジワイズ セラピューティクス， インコーポレイテッド | キナゾリンジオン化合物およびその使用 |
| KR20250174911A (ko) | 2023-03-27 | 2025-12-15 | 엣지와이즈 테라퓨틱스, 인크. | 퀴놀리논 아미드 화합물 및 이의 용도 |
| US11986474B1 (en) | 2023-06-27 | 2024-05-21 | Cytokinetics, Incorporated | Methods for treating heart failure by administering cardiac sarcomere activators |
| WO2026050494A1 (en) | 2024-08-29 | 2026-03-05 | Cytokinetics, Incorporated | Omecamtiv mecarbil for use in treating heart failure by activating cardiac sarcomere |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4450150A (en) | 1973-05-17 | 1984-05-22 | Arthur D. Little, Inc. | Biodegradable, implantable drug delivery depots, and method for preparing and using the same |
| WO1999040942A1 (en) | 1998-02-10 | 1999-08-19 | Yoshitomi Pharmaceutical Industries, Ltd. | Preparations with controlled release |
| GB2344287A (en) | 1998-12-03 | 2000-06-07 | Ferring Bv | Controlled release pharmaceutical formulation |
| WO2004033036A2 (en) | 2002-10-04 | 2004-04-22 | Microchips, Inc. | Medical device for controlled drug delivery and cardiac monitoring and/or stimulation |
| US7507735B2 (en) | 2004-06-17 | 2009-03-24 | Cytokinetics, Inc. | Compounds, compositions and methods |
| TW200808321A (en) | 2005-12-15 | 2008-02-16 | Cytokinetics Inc | Certain chemical entities, compositions and methods |
| CA2651283A1 (en) | 2006-05-15 | 2007-11-22 | Wisconsin Alumni Research Foundation | Pulmonary delivery of 1.alpha.,25-dihydroxyvitamin d3 and co-administration of parathyroid hormone or calcitonin |
| FR2902092B1 (fr) | 2006-06-07 | 2008-09-05 | Sapelem Soc Par Actions Simpli | Appareil de manutention de charge |
| WO2008130158A1 (en) | 2007-04-19 | 2008-10-30 | Dong-A Pharmaceutical. Co., Ltd | A biodegradable microsphere composition suitable for the controlled release of glucose controlling peptide and formulation thereof |
| EP3821882A1 (en) | 2013-03-14 | 2021-05-19 | Amgen Inc. | Heterocyclic compounds and their uses |
| JP6634368B2 (ja) * | 2013-03-14 | 2020-01-22 | アムジエン・インコーポレーテツド | 複素環式化合物及びそれらの使用 |
| EP3250557B1 (en) | 2015-01-29 | 2024-11-20 | Signal Pharmaceuticals, LLC | Isotopologues of 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide |
| JP6858716B2 (ja) | 2015-06-26 | 2021-04-14 | アムジエン・インコーポレーテツド | 心筋ミオシン活性化剤と洞房結節Ｉｆ電流阻害剤の併用療法 |
| AU2018214629A1 (en) | 2017-02-06 | 2019-08-22 | Acceleron Pharma Inc. | Compositions and methods for treating heart failure |
| JP2020526483A (ja) | 2017-06-30 | 2020-08-31 | アムジエン・インコーポレーテツド | 心筋節活性化剤で心不全を治療する方法 |
| MX2021009594A (es) | 2017-06-30 | 2022-10-24 | Amgen Inc | Sintesis de omecamtiv mecarbil. |
| DK3594199T3 (da) | 2018-07-09 | 2020-09-14 | Fis Fabbrica Italiana Sintetici Spa | Krystallinsk 2-flour-3-nitrotoluen og proces til forberedelse deraf |
| WO2020014406A1 (en) | 2018-07-12 | 2020-01-16 | Assia Chemical Industries Ltd. | Solid state forms of omecamtiv mecarbil & omecamtiv mecarbil dihcl |
| EP3599243B1 (en) | 2018-07-26 | 2023-04-12 | CVIE Therapeutics Limited | 17beta-heterocyclyl-digitalis like compounds for the treatment of heart failure |
| EP3837009A1 (en) | 2018-08-17 | 2021-06-23 | Amgen, Inc | Salts and crystal forms of omecamtiv mecarbil |
| US12442027B2 (en) | 2018-12-18 | 2025-10-14 | Amgen Inc. | Method of reducing aromatic nitro compounds |
| CN112118846B (zh) | 2019-03-05 | 2024-04-16 | 风树疗法公司 | 治疗急性心力衰竭(ahf)用的含伊司他肟的静脉内制剂 |
| US20220340542A1 (en) | 2019-09-19 | 2022-10-27 | Synthon B.V. | Salts of omecamtiv mecarbil and solid forms thereof |
| US20220348543A1 (en) | 2019-09-19 | 2022-11-03 | Synthon B.V. | Salts of omecamtiv mecarbil and solid forms thereof |
| WO2021070123A1 (en) | 2019-10-09 | 2021-04-15 | Dr. Reddy’S Laboratories Limited | Solid forms of omecamtiv mecarbil dihydrochloride and processes thereof |
| US20220411374A1 (en) | 2019-10-09 | 2022-12-29 | Dr. Reddy's Laboratories Limited | Alternate processes for the preparation of omecamtiv mecarbil |
| CA3157629A1 (en) | 2019-11-10 | 2021-05-14 | MyoKardia, Inc. | Methods of treatment with myosin modulator |
| GB201918853D0 (en) | 2019-12-19 | 2020-02-05 | Lund Lars H | Methods of treatment |
| CN114929671B (zh) | 2020-01-03 | 2024-04-16 | 苏州科睿思制药有限公司 | 化合物i二盐酸盐的共晶及其制备方法和用途 |
| WO2021163172A1 (en) | 2020-02-10 | 2021-08-19 | Amgen Inc. | Omecamtiv mecarbil tablet |
| IL302850A (en) | 2020-11-12 | 2023-07-01 | Amgen Inc | Methods of treating heart failure by administering OMECAMTIV MECARBIL |
| AU2022232919A1 (en) | 2021-03-10 | 2023-10-19 | Amgen Inc. | Synthesis of omecamtiv mecarbil |
| WO2023205291A2 (en) | 2022-04-21 | 2023-10-26 | The Board Of Regents Of The University Of Oklahoma | Targeting myocardial tissue for delivery of therapeutic and imaging agents |
| WO2024081611A1 (en) | 2022-10-11 | 2024-04-18 | Cytokinetics, Incorporated | Methods for treating heart failure by administering cardiac sarcomere activators |
| US11986474B1 (en) * | 2023-06-27 | 2024-05-21 | Cytokinetics, Incorporated | Methods for treating heart failure by administering cardiac sarcomere activators |
-
2018
- 2018-06-29 JP JP2019570045A patent/JP2020526483A/ja active Pending
- 2018-06-29 CA CA3068588A patent/CA3068588A1/en active Pending
- 2018-06-29 SM SM20250067T patent/SMT202500067T1/it unknown
- 2018-06-29 ES ES18745732T patent/ES3008457T3/es active Active
- 2018-06-29 MD MDE20200488T patent/MD3645002T2/ro unknown
- 2018-06-29 PT PT187457320T patent/PT3645002T/pt unknown
- 2018-06-29 AU AU2018290983A patent/AU2018290983B2/en active Active
- 2018-06-29 EP EP24209435.7A patent/EP4512470A3/en active Pending
- 2018-06-29 PL PL18745732.0T patent/PL3645002T3/pl unknown
- 2018-06-29 FI FIEP18745732.0T patent/FI3645002T3/fi active
- 2018-06-29 BR BR112019028046-4A patent/BR112019028046A2/pt not_active Application Discontinuation
- 2018-06-29 CN CN201880053343.0A patent/CN110996953A/zh active Pending
- 2018-06-29 RS RS20250023A patent/RS66581B1/sr unknown
- 2018-06-29 SI SI201831198T patent/SI3645002T1/sl unknown
- 2018-06-29 MA MA49508A patent/MA49508B1/fr unknown
- 2018-06-29 LT LTEPPCT/US2018/040181T patent/LT3645002T/lt unknown
- 2018-06-29 WO PCT/US2018/040181 patent/WO2019006235A1/en not_active Ceased
- 2018-06-29 DK DK18745732.0T patent/DK3645002T3/da active
- 2018-06-29 HR HRP20241729TT patent/HRP20241729T1/hr unknown
- 2018-06-29 HU HUE18745732A patent/HUE069805T2/hu unknown
- 2018-06-29 US US16/625,958 patent/US11576910B2/en active Active
- 2018-06-29 EP EP18745732.0A patent/EP3645002B1/en active Active
- 2018-06-29 MX MX2020000190A patent/MX2020000190A/es unknown
-
2020
- 2020-01-08 MX MX2022015115A patent/MX2022015115A/es unknown
-
2023
- 2023-01-17 US US18/155,483 patent/US12295952B2/en active Active
- 2023-03-15 JP JP2023040600A patent/JP2023088944A/ja active Pending
- 2023-05-05 US US18/313,267 patent/US11931358B2/en active Active
-
2024
- 2024-02-15 AU AU2024200991A patent/AU2024200991B2/en active Active
-
2025
- 2025-04-18 US US19/183,619 patent/US20250255862A1/en active Pending
- 2025-07-18 JP JP2025121073A patent/JP2025165979A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2020000190A (es) | Métodos para tratar la insuficiencia cardíaca con activadores de sarcómero cardíaco. | |
| CY1125213T1 (el) | Μεθοδοι θεραπειας καρκινου του μαστου ar+ | |
| MX2022007968A (es) | Dosificacion de gamma-hidroxibutirato (ghb). | |
| CL2017002904A1 (es) | Métodos y kits para tratar la depresión | |
| MX2019005594A (es) | Agentes, usos y metodos para el tratamiento de la sinucleinopatia. | |
| MX2022008868A (es) | Tratamiento del cancer con tg02. | |
| EA201890869A3 (ru) | Применение ингибиторов тирозинкиназы брутона (btk) | |
| MY206794A (en) | Combination hbv therapy | |
| EA202191632A1 (ru) | Ахромосомные динамические активные системы | |
| AR102767A1 (es) | Inhibidores de ezh2 | |
| CY1123350T1 (el) | Θεραπευτικα σχηματα καi μεθοδοι αντιμετωπισης σκληρυνσης κατα πλακας μεσω χρησης οφατουμουμαμπης | |
| MX2022006817A (es) | Formulaciones/composiciones que comprenden un inhibidor de btk. | |
| CL2017001756A1 (es) | Régimen de dosificación para antagonistas de madcam. | |
| JOP20180127A1 (ar) | صيغ صلبة من منشط محلقة غوانيليل قابل للذوبان (sGC) | |
| EA201792641A1 (ru) | Ингибитор оси igfbp3/tmem219 и диабет | |
| EA202090673A1 (ru) | Стратификация генотипа при лечении и профилактике диабета | |
| CY1125307T1 (el) | Μεθοδος αγωγης ασθενων με συγχορηγηση ριβαροξαμπανης και βεραπαμιλης | |
| SV2018005702A (es) | Compuestos de 1,3,4-tiadiazol y su uso en el tratamiento del cancer | |
| MX2022006312A (es) | Inhibidores del receptor de hidrocarburos de arilo (ahr) y usos de los mismos. | |
| MX2020002741A (es) | Uso de gaboxadol en el tratamiento de narcolepsia. | |
| WO2021055554A3 (en) | Methods to improve patient response to immune checkpoint inhibitors and functional tests to predict response | |
| EA202192961A1 (ru) | Ребамипид для применения в профилактике и/или лечении синуклеинопатий | |
| BR112018070786A2 (pt) | métodos de tratamento com agonistas do receptor de cb2 seletivos | |
| WO2018067946A8 (en) | METHODS OF TREATING PATIENTS USING RETINOIC ACID ALPHA RECEPTOR AGONIST AND ANTI-CD38 ANTIBODY | |
| MX2023012415A (es) | Metodos de uso del dantroleno para tratar la exposicion a agente nervioso. |